Improving function: a new treatment era for multiple ... [Lancet. 2009] - PubMed

loading

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. [Lancet. 2009]
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators. Lancet. 2009 Feb 28; 373(9665):732-8.
Dalfampridine (Ampyra) for MS. [Med Lett Drugs Ther. 2010]
Dalfampridine (Ampyra) for MS.
. Med Lett Drugs Ther. 2010 Sep 20; 52(1347):73-4.
Review Sustained release oral fampridine in the treatment of multiple sclerosis. [Expert Opin Pharmacother. 2009]
Review Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ. Expert Opin Pharmacother. 2009 Aug; 10(12):2025-35.
4-aminopyridine: new life for an old drug. [Ann Neurol. 2010]
4-aminopyridine: new life for an old drug.
Hauser SL, Johnston SC. Ann Neurol. 2010 Jul; 68(1):A8-9.
Review Dalfampridine extended release: in multiple sclerosis. [CNS Drugs. 2010]
Review Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM, Keating GM. CNS Drugs. 2010 Oct; 24(10):883-91.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Improving function: a new treatment era for multiple sclerosis?
Improving function: a new treatment era for multiple sclerosis?
Lancet. 2009 Feb 28 ;373(9665):697-8.

PubMed
Neodymium-doped yttrium-aluminium-garnet laser irradiation abolishes the increas...
Neodymium-doped yttrium-aluminium-garnet laser irradiation abolishes the increase in interleukin-6 levels caused by peptidoglycan through the p38 mitogen-activated protein kinase pathway in human pulp cells.
J Endod. 2009 Mar ;35(3):373-6.

PubMed
Obstructive sleep apnea and inflammation.
Obstructive sleep apnea and inflammation.
Prog Cardiovasc Dis. 2009 Mar-Apr ;51(5):392-9.

PubMed
N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropath...
N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Am Heart J. 2009 Mar ;157(3):576-83. Epub 2009 Feb 6 .

PubMed
Blood pressure paradox in patients with non-ST-segment elevation acute coronary ...
Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative.
Am Heart J. 2009 Mar ;157(3):525-31. Epub 2009 Jan 8 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed